-- GCI Liberty（股票代码：GLIBA，GLIBK）旗下的GCI Holdings子公司和Grain Management周三宣布，双方已达成协议，GCI将收购阿拉斯加光纤基础设施供应商Q Gateway Intermediate（简称Quintillion）。 两家公司表示，此次交易将使GCI完全拥有Quintillion，并将两家公司的光纤网络合并，从而提升阿拉斯加地区的网络连接可靠性。 该交易的企业价值为3.1亿美元，具体金额将根据惯例进行营运资本和其他调整。GCI还将偿还与诺姆至荷马快速铁路项目相关的部分建设成本，最高可达5000万美元。如果达到特定的财务目标，GCI可能在2028年、2029年和2031年支付额外款项。两家公司表示，协议签署后不久，GCI将向Quintillion提供1.6亿美元的无担保贷款。 声明称，该交易将在获得监管部门批准并满足特定条件后完成。
Price: $37.07, Change: $+0.31, Percent Change: +0.86%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.